NASDAQ: PHAR
Pharming Group Nv Stock

$10.00-0.01 (-0.1%)
Updated Jul 10, 2025
PHAR Price
$10.00
Fair Value Price
N/A
Market Cap
$680.31M
52 Week Low
$6.65
52 Week High
$12.61
P/E
-41.84x
P/B
2.8x
P/S
1.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$364.44M
Earnings
-$15.34M
Gross Margin
89%
Operating Margin
-1.09%
Profit Margin
-4.4%
Debt to Equity
0.88
Operating Cash Flow
$7M
Beta
0.52
Next Earnings
Jul 31, 2025
Ex-Dividend
N/A
Next Dividend
N/A

PHAR Overview

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PHAR's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
PHAR
Ranked
Unranked of 475

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important PHAR news, forecast changes, insider trades & much more!

PHAR News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PHAR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PHAR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHAR is good value based on its book value relative to its share price (2.8x), compared to the US Biotechnology industry average (4.7x)
P/B vs Industry Valuation
PHAR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PHAR due diligence checks available for Premium users.

Valuation

PHAR fair value

Fair Value of PHAR stock based on Discounted Cash Flow (DCF)

Price
$10.00
Fair Value
$1.02
Overvalued by
875.82%
PHAR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PHAR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-41.84x
Industry
-162x
Market
30.8x

PHAR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.8x
Industry
4.7x
PHAR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PHAR's financial health

Profit margin

Revenue
$86.0M
Net Income
-$16.0M
Profit Margin
-18.6%
PHAR's Earnings (EBIT) of -$3.96M... subscribe to Premium to read more.
Interest Coverage Financials
PHAR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$438.2M
Liabilities
$204.2M
Debt to equity
0.88
PHAR's short-term assets ($243.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHAR's short-term assets ($243.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHAR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$252.2k
Investing
$10.5M
Financing
-$7.3M
PHAR's operating cash flow ($6.91M)... subscribe to Premium to read more.
Debt Coverage Financials

PHAR vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PHAR$680.31M-0.10%-41.84x2.80x
PHATF$676.50M+3.42%-1.87x-2.00x
MAZED$684.99M+3.71%N/A2.35x
URGND$675.01M+6.01%-4.91x-14.53x
MGTXC$692.75M+2.99%-3.72x20.93x

Pharming Group Nv Stock FAQ

What is Pharming Group Nv's quote symbol?

(NASDAQ: PHAR) Pharming Group Nv trades on the NASDAQ under the ticker symbol PHAR. Pharming Group Nv stock quotes can also be displayed as NASDAQ: PHAR.

If you're new to stock investing, here's how to buy Pharming Group Nv stock.

What is the 52 week high and low for Pharming Group Nv (NASDAQ: PHAR)?

(NASDAQ: PHAR) Pharming Group Nv's 52-week high was $12.61, and its 52-week low was $6.65. It is currently -20.7% from its 52-week high and 50.38% from its 52-week low.

How much is Pharming Group Nv stock worth today?

(NASDAQ: PHAR) Pharming Group Nv currently has 680,308,735 outstanding shares. With Pharming Group Nv stock trading at $10.00 per share, the total value of Pharming Group Nv stock (market capitalization) is $680.31M.

Pharming Group Nv stock was originally listed at a price of $16.70 in Dec 23, 2020. If you had invested in Pharming Group Nv stock at $16.70, your return over the last 4 years would have been -40.12%, for an annualized return of -12.03% (not including any dividends or dividend reinvestments).

How much is Pharming Group Nv's stock price per share?

(NASDAQ: PHAR) Pharming Group Nv stock price per share is $10.00 today (as of Jul 10, 2025).

What is Pharming Group Nv's Market Cap?

(NASDAQ: PHAR) Pharming Group Nv's market cap is $680.31M, as of Jul 11, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pharming Group Nv's market cap is calculated by multiplying PHAR's current stock price of $10.00 by PHAR's total outstanding shares of 680,308,735.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.